Sale of Pharmalink Consulting to Genpact Limited

Deal typeM&A
IndustryLife Sciences

BDO is pleased to announce that our M&A team acted as lead adviser to the shareholders of the Pharmalink Consulting group of companies ("Pharmalink") on the successful sale of the business to Genpact Limited (NYSE: G), a global leader in transforming and running business processes and operations. The deal was signed on 23rd April for an undisclosed amount, with completion expected to follow in the next few weeks.   Pharmalink’s specialised domain expertise, speed, responsiveness and ability to scale have made it a leading provider for sustainable outsourcing of regulatory affairs services. Its clients include nearly all of the twenty largest global life sciences companies. Its specialised expertise includes the end-to-end range of regulatory services including strategy, chemistry manufacturing & controls (CMC), regulatory operations and publishing & technology services.    

“I was very impressed with BDO – the team’s professionalism and dedication was resolute throughout the process, and I would recommend them to anyone as first class advisers. I would like to thank them for their support and their contribution to a magnificent result.

Genpact represents an ideal partner for the business as we look to embark upon our next phase of international growth. I am sure that Genpact will achieve huge success in driving the business forward by working closely with the excellent management team and capitalising upon our incumbent position as a market leading provider of regulatory services to the life sciences industry.”

Peter Griffin, Chairman & Founder, Pharmalink Consulting